# Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

> **NCT04205968** · PHASE2 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 94 (estimated)

## Conditions studied

- Metastatic Small Intestinal Adenocarcinoma
- Stage III Small Intestinal Adenocarcinoma AJCC v8
- Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
- Stage IIIB Small Intestinal Adenocarcinoma AJCC v8
- Stage IV Small Intestinal Adenocarcinoma AJCC v8

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Leucovorin
- **DRUG:** Leucovorin Calcium
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT04205968
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04205968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04205968, "Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04205968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*